The Canadian Technology Accelerator in Boston (CTA@Boston) is an award-winning immersion program that drives growth for small and medium sized Canadian companies. Operated by the Consulate General of Canada in Boston, the program has assisted over 77 Canadian companies since its founding in 2013 with its unique business acceleration services that help companies commercialize or scale their business in the US market.



Consulate General of Canada (CTA Boston)

New Row

Contact expert @[Full Name](fullname), @[Job Title](job_title) at @[Organization](organization) for media, speaking, professional opportunities and more.

@[Full Name](fullname) at @[Organization](organization) | Contact Form

Expert Inquiry

Open Sans

With over 28 years of investment, consulting and entrepreneurial experience in the health care industry, Gerry has helped build life sciences companies at all stages of development. He focuses on investments in a range of therapeutic areas in the biotechnology and medical device sectors, including infectious diseases, neurology, cardiovascular disease, gene therapy and medical robotics. Gerry manages Lumira Ventures’ Boston office, which he established when he joined the firm in 2002.

Prior to joining Lumira Ventures, Gerry was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues including portfolio management, corporate partnering, R&D productivity, new product launches, disease management initiatives, acquisitions and post-merger integration. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston in New York where his clients included public and private health care companies.

Business Strategy

Medical Devices

Pharmaceutical Industry

Drug Development

Commercialization

Venture Capital

Start-Ups

Corporate Development

Strategic Planning

Product Development

Strategy

HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing

LICENSING & VENTURES GROUP HIRE SEED FUND DIRECTOR TO SHEPHERD UVA INNOVATIONS

Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy

Managing Director

Select Inquiry Type